This site is intended for healthcare professionals outside the U.S.
ESTEEM® 2 study. Data as observed; includes patients who were randomized to OTEZLA 30 mg BID or placebo with the presence of moderate to very severe scalp psoriasis at baseline (ScPGA ≥3; n = 269/411, 65.5%), were PASI-50 responders at week 32, and who continued to receive OTEZLA 30 mg BID up to week 52.
At week 16, ScPGA score of 0 (clear) or 1 (minimal) achievement was significantly greater with OTEZLA 30 mg BID (40.9%, 72/176) vs placebo (17.2%, 16/93); P < 0.0001; full analysis set, LOCF.
ESTEEM, Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis; LOCF, last observation carried forward; PASI, Psoriasis Area and Severity Index; ScPGA, Scalp Physician’s Global Assessment.
Reference: 1. Crowley J, Gooderham M, Wasel N, et al. Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients With Nail, Scalp, and Palmoplantar Psoriasis: 52-Week Results From the ESTEEM 2 Trial. Presented at: the 73rd Annual Meeting of the American Academy of Dermatology; March 20-24, 2015; San Francisco, CA.
Please choose a country